PAVmed Inc. (PAVM) Stock

PAVmed Inc. (PAVM) is a Healthcare stock trading at $5.30 (as of 2026-08-20), with a market capitalization of $42.42M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PAVmed Inc. is a medical device company in the United States focused on diagnostic and therapeutic technologies for conditions in the esophagus, carpal tunnel, and other clinical areas. Its product portfolio includes CarpX, EsoCheck, EsoGuard, and EsoCure, along with additional device and monitoring platforms such as Veris and implantable vascular access systems.

Understand PAVmed Inc.: how it makes money

PAVmed Inc. develops and markets specialized medical devices and diagnostic assays for conditions like carpal tunnel syndrome and early detection of esophageal cancer and Barrett's Esophagus, and it generates revenue through sales of its product portfolio (including CarpX, EsoCheck, EsoGuard, and others).

The profit model is primarily driven by whether PAVmed can convert its specialized lead products and its pipeline (devices and a sequencing-based DNA assay) into recurring commercial product sales, since the company’s product revenue is the core output of its R&D and commercialization efforts.

Business quality (Weak): Limited disclosure for this dataset (no official reportable segments or operational KPIs provided), so the investor lens is mainly the latest-quarter financial loss profile and the breadth of the product and pipeline portfolio.

Bull case

  • Broad, condition-specific product portfolio: Lead products cover percutaneous treatment for carpal tunnel syndrome (CarpX) and esophageal disease detection using an esophageal cell collection device (EsoCheck) plus a bisulfite-converted next-generation sequencing DNA assay (EsoGuard).
  • Pipeline extends beyond detection into treatment and related technologies: Pipeline products listed include EsoCure (esophageal ablation for dysplastic BE), PortIO (implantable intraosseous vascular access device), and NextFlo (disposable infusion platform technology).

Bear case

  • Latest-quarter profitability is materially negative: For the period ended 2026-03-31, reported gross_margin_pct is -340.9 and operating_margin_pct is -36522.7, indicating significant losses and cost pressure relative to revenue in the provided data.
  • No trackable operating metrics or segment revenue detail in the provided facts: The dataset includes no operational_kpi_candidates and no segment_revenue_candidates_b, which makes it harder for investors to monitor operational drivers beyond the loss metrics shown.
Valuation — source: SEC EDGAR (first-party)
Price$5.30
Market Cap$42.42M
Price / Book2.20
Price / Sales378.74
FCF Yield-18.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$71000.00
Net Margin564.8%
Revenue Growth (YoY)450.0%
EPS Growth (YoY)17.6%
FCF Growth (YoY)125.6%
Financial Health — source: SEC EDGAR
Altman Z-Score-10.33 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderTwo Seas Capital LP ($4.68M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOLishan Aklog
Employees39
CountryUS
IPO Date2016-07-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Sensus Healthcare, Inc. (SRTS)
  • Spectral AI, Inc. (MDAI)
  • Nephros, Inc. (NEPH)
  • Xtant Medical Holdings, Inc. (XTNT)
  • SANUWAVE Health, Inc. (SNWV)
  • Accuray Incorporated (ARAY)
  • Plus Therapeutics, Inc. (PSTV)
  • HeartBeam, Inc. (BEAT)
PAVM earnings history · PAVM institutional & insider holders · PAVM KPIs & operating metrics · PAVM financials · PAVM investor presentations & press releases · PAVM SEC filings · PAVM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.